Palonosetron
| Evidence Level: L4 | Predicted Indications: 4 |
Table of Contents
Palonosetron: Migraine disorder
One-Sentence Summary
Palonosetron is a second-generation 5-HT3 receptor antagonist, a class of drug used to prevent nausea and vomiting. The TxGNN model predicts it may be effective for migraine disorder, but there are no registered clinical trials and the only directly relevant publication is a case report describing palonosetron-induced migraine-type headache, which points in the opposite direction of benefit.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9974 |
| Evidence Level | L4 |
| India Market Status | Listed in a compiled Indian medicine price dataset (12 of 12) – CDSCO approval status is not included in this data |
| Number of Listed Products | 12 (valid: 12) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, palonosetron is a second-generation 5-HT3 receptor antagonist. These receptors are found on trigeminal afferent nerves and in the brainstem circuits that control vomiting, which gives a theoretical link to migraine pathophysiology and to migraine-associated nausea.
However, this link is weak. The high TxGNN score (0.9974) reflects a network-based prediction, not clinical data. The only retrieved publication (PMID 21132477) reports that palonosetron induced migraine-type headache. That is a safety signal opposite to therapeutic benefit.
The other predicted indications are even less supported. Migraine with brainstem aura is a prediction driven only by its similarity to the general migraine node. Atrophoderma vermiculata and ulerythema ophryogenesis are rare skin disorders with no plausible 5-HT3 link and probably reflect TxGNN model (deep learning) artifacts.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21132477 | 2011 | Case report | Can J Anaesth | Palonosetron-induced migraine-type headache; a safety signal, not evidence of efficacy |
| 42748473 | 2026 | Review | Eur Heart J Cardiovasc Pharmacother | Review of antiemetic-associated QT prolongation with a risk-stratified prescribing framework; relevant to cardiac safety, not migraine efficacy |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 178921 | Palibout 0.25 Injection | Vial of 5 ml injection | Not specified |
| 8975 | Aloxy Capsule | Strip of 10 capsules | Not specified |
| 178192 | Palostar 0.25mg Injection | Vial of 5 ml injection | Not specified |
| 44732 | Chepatron 0.25mg Injection | Vial of 1 ml injection | Not specified |
| 76668 | Emecad 0.25mg Injection | Vial of 5 ml injection | Not specified |
Twelve valid single-ingredient registrations are listed in total. Both injectable and oral forms are marketed.
Safety Considerations
- Drug Interactions: 398 interactions were recorded. Major-level interactions include:
- Fentanyl, alfentanil, tramadol and dextromethorphan
- Almotriptan and sumatriptan
- Amiodarone, amisulpride, amitriptyline and anagrelide
Moderate-level interactions include abiraterone, codeine, dihydrocodeine, famotidine, formoterol, adenosine, salbutamol, propofol and loperamide.
- Cardiac safety: A 2026 review indicates that antiemetics can prolong the QT interval. This is relevant given the QT-related interactions above (for example amiodarone and amisulpride).
- Headache signal: Palonosetron has been reported to induce migraine-type headache (PMID 21132477).
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no clinical trials, and the only directly relevant report suggests palonosetron can trigger migraine-type headache rather than treat it. The remaining predicted indications have no supporting evidence.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India Pharma source (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Preclinical or clinical evidence that 5-HT3 antagonism by palonosetron benefits migraine, which would need to address the reported headache-induction signal
- A QT-risk assessment if any development is considered, given the interacting QT-prolonging drugs
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.